Group 1 - The core point of the article is that Kelun Pharmaceutical announced a cash dividend distribution plan, where it will distribute 1.26 RMB per 10 shares to all shareholders, based on a total share count of approximately 1.591 billion shares after excluding repurchased shares [1] - The record date for the dividend is set for October 20, 2025, and the ex-dividend date is October 21, 2025 [1] - As of the report, Kelun Pharmaceutical has a market capitalization of 55.5 billion RMB [1] Group 2 - For the first half of 2025, the revenue composition of Kelun Pharmaceutical is as follows: 89.66% from the pharmaceutical manufacturing sector, 7.01% from research and development projects, and 3.33% from other businesses [1]

1.因四川科伦药业股份有限公司（以下简称"公司"）回购专用证券账户中 的股份不参与 2025 年度中期权益分派，公司本次实际现金分红的总金额=实际参 与分配的总股本×分配比例，即 200,438,432.2080 元=1,590,781,208 股×0.126 元 /股。 2.本次权益分派实施后，根据股票市值不变原则，实施权益分派前后公司总 股本保持不变，现金分红总额分摊到每一股的比例将减小，因此，本次权益分派 实施后除权除息价格计算时，按股权登记日的总股本折算的每股现金红利=实际 现金分红总金额÷股权登记日的总股本=200,438,432.2080 元÷1,598,053,372 股 =0.1254266 元/股，即：本次权益分派实施后的除权除息价格=股权登记日收盘价 0.1254266 元/股。 一、 股东大会审议通过利润分配方案情况 公司2025年度中期权益分派方案已于2025年9月15日经公司2025年第二次临 时股东大会审议通过，本次权益分派方案的具体内容为：公司以利润分配实施公 告确定的股权登记日当日的可参与分配的股本数量为基数，向全体股东每10股派 发现金红利1.260000元（含税）；不转增， ...

Core Viewpoint - The company announced that its subsidiary, Sichuan Kelun-Botai Biopharmaceutical Co., Ltd., received approval for a third indication of its antibody-drug conjugate, sac-TMT (also known as SKB264/MK-2870), for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1] Company Summary - The approved drug, sac-TMT, targets TROP2 and is positioned to address a significant patient population in the NSCLC segment [1] - This approval marks a significant milestone for the company, expanding its product offerings in the oncology space [1] Industry Summary - The approval of sac-TMT aligns with the growing trend of developing targeted therapies for cancer treatment, particularly in the NSCLC market [1] - The NSCLC market is increasingly competitive, with a focus on innovative therapies that can provide options for patients who have limited treatment responses [1]

公告显示，芦康沙妥珠单抗(sac-TMT)是迄今为止全球首个且唯一对比含铂双药化疗显示出显著的总生 存期(OS)获益，并且已获批用于仅接受过TKI治疗后进展(2L)的晚期NSCLC的ADC。在预设的OS期中分 析中，与目前含铂双药化疗标准治疗相比，芦康沙妥珠单抗(sac-TMT)单一疗法在无进展生存期和总生 存期均具有显著统计学意义和临床意义的改善，显著延长此类患者的无进展生存期和总生存期。 北京商报讯(记者丁宁)10月12日晚间，科伦药业（002422）发布公告称，公司近日获悉，公司控股子公 司四川科伦博泰生物医药股份有限公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙 妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱)获国家药品监督管理局(NMPA)批准第三项适应 症，用于治疗经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后进展的EGFR基因突变阳性的 局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。 ...

科伦药业（002422）(002422.SZ)发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股 份有限公司(简称"科伦博泰")靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗 (sac-TMT，亦称SKB264/MK-2870)(佳泰莱)获国家药品监督管理局(NMPA)批准第三项适应症，用于治 疗经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后进展的EGFR基因突变阳性的局部晚期或 转移性非鳞状非小细胞肺癌(NSCLC)成人患者。 芦康沙妥珠单抗(sac-TMT)是迄今为止全球首个且唯一对比含铂双药化疗显示出显著的总生存期(OS)获 益，并且已获批用于仅接受过TKI治疗后进展(2L)的晚期NSCLC的ADC。在预设的OS期中分析中，与 目前含铂双药化疗标准治疗相比，芦康沙妥珠单抗(sac-TMT)单一疗法在无进展生存期和总生存期均具 有显著统计学意义和临床意义的改善，显著延长此类患者的无进展生存期和总生存期。 ...

科伦药业(002422.SZ)发布公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司 (简称"科伦博泰")靶向人滋养细胞表面抗原 2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT， 亦称SKB264/MK-2870)(佳泰莱®)获国家药品监督管理局(NMPA)批准第三项适应症，用于治疗经表皮生 长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞 状非小细胞肺癌(NSCLC)成人患者。 芦康沙妥珠单抗(sac-TMT)是迄今为止全球首个且唯一对比含铂双药化疗显示出显著的总生存期(OS)获 益，并且已获批用于仅接受过 TKI 治疗后进展(2L)的晚期NSCLC 的 ADC。在预设的 OS 期中分析中， 与目前含铂双药化疗标准治疗相比，芦康沙妥珠单抗(sac-TMT)单一疗法在无进展生存期和总生存期均 具有显著统计学意义和临床意义的改善，显著延长此类患者的无进展生存期和总生存期。 ...

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the third indication of the antibody-drug conjugate (ADC) sac-TMT, targeting TROP2, for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1][2] Group 1 - The approval is based on a randomized, open-label, multicenter Phase III clinical study (OptiTROP-Lung04), which will be presented at the 2025 European Society for Medical Oncology (ESMO) conference [2] - The study aims to evaluate the efficacy and safety of sac-TMT administered as a monotherapy compared to pemetrexed combined with platinum-based therapy in patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who failed EGFR-TKI treatment [2] - Sac-TMT is the first and only ADC to show significant overall survival (OS) benefits compared to platinum-based doublet chemotherapy in this patient population [1][2] Group 2 - In March 2025, sac-TMT was approved by NMPA for patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who progressed after EGFR-TKI and platinum-based chemotherapy [2] - The monotherapy with sac-TMT significantly extended the overall survival of these patients compared to standard treatment [2] - Another Phase III registration study of sac-TMT combined with osimertinib as first-line treatment for EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC has completed patient enrollment in China [2]

格隆汇10月12日丨科伦药业(002422.SZ)公告，四川科伦药业股份有限公司(以下简称"公司")近日获悉， 公司控股子公司四川科伦博泰生物医药股份有限公司(以下简称"科伦博泰")靶向人滋养细胞表面抗原 2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱)获国家药品 监督管理局(NMPA)批准第三项适应症，用于治疗经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI) 治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。 本次批准是基于一项随机、开放标签、多中心III期临床研究(OptiTROP-Lung04)，该研究已入选2025年 欧洲肿瘤内科学会(ESMO)大会最新突破性摘要(LBA)，并将以主席论坛(PresidentialSymposium)口头报 告(报告编号：LBA5)的形式发布。OptiTROP-Lung04研究旨在评估芦康沙妥珠单抗(sac-TMT)单一疗法 每两周(Q2W)5mg/kg静脉注射对比培美曲塞联合铂类治疗经EGFR-TKI治疗失败的EGFR突变的局部晚期 或转移性非鳞状N ...

四川科伦药业股份有限公司 关于子公司核心产品 TROP2 ADC 芦康沙妥珠单抗(sac-TMT) 获国家药品监督管理局批准第三项适应症（用于治疗 EGFR-TKI 治 疗后进展的 EGFR 突变非小细胞肺癌）上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：002422 证券简称：科伦药业 公告编号：2025-073 本 次 批 准 是 基 于 一 项 随 机 、 开 放 标 签 、 多 中 心 III 期 临 床 研 究 (OptiTROP-Lung04)，该研究已入选 2025 年欧洲肿瘤内科学会(ESMO)大会最新 突破性摘要(LBA)，并将以主席论坛(Presidential Symposium)口头报告（报告编号： LBA5）的形式发布。OptiTROP-Lung04 研究旨在评估芦康沙妥珠单抗(sac-TMT) 单 一 疗 法 每两 周 (Q2W) 5mg/kg 静 脉 注 射 对比 培 美 曲 塞 联 合 铂类 治 疗 经 EGFR-TKI 治疗失败的 EGFR 突变的局部晚期或转移性非鳞状 NSCLC 患者的有 效性和安全 ...

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate, sac-TMT (also known as SKB264/MK-2870), for a third indication in treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1] Group 1 - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai, has developed an ADC targeting TROP2 [1] - The newly approved indication is specifically for EGFR gene mutation-positive NSCLC patients [1] - This approval marks the third indication for sac-TMT, enhancing its therapeutic applications [1]